本发明涉及公式I的取代咪唑[1,5-a][1,2,4]三唑并[1,5-d][1,4]苯二氮平衍生物,其中R1为氢、卤素、较低烷基、较低炔基、环烷基、杂环烷基、苄基、氰基、较低烷氧基、OCF3、—NHR、—NHC(O)R或—NHSO2R;R2为卤素取代的较低烷基;R3为氢、甲基或芳基;R为较低烷基、环烷基或芳基;以及其药学上可接受的酸盐。这些化合物对GABA A α5受体结合位点具有高亲和力和选择性,并可能用作认知增强剂或用于治疗认知障碍、焦虑、精神分裂症或阿尔茨海默病。
Use of active pharmaceutical compounds for the treatment of central nervous system conditions
申请人:F. Hoffmann-La Roche AG
公开号:EP2457569A1
公开(公告)日:2012-05-30
The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions caused by neurodevelopmental defects which result in excessive GABAergic inhibition in the cortex and hippocampus.
本发明涉及选择性GABA A α5负异位调节剂的药物用途,用于治疗、预防和/或延缓由神经发育缺陷引起的中枢神经系统(CNS)疾病的进展,神经发育缺陷导致大脑皮层和海马中GABA能抑制过度。
IMIDAZO-BENZODIAZEPINE DERIVATIVES
申请人:F.Hoffmann-La Roche AG
公开号:EP1805184B1
公开(公告)日:2013-01-09
USE OF ACTIVE PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS